LAVA Therapeutics (NASDAQ:LVTX) Short Interest Down 22.5% in December

LAVA Therapeutics (NASDAQ:LVTX) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 45,500 shares, a decrease of 22.5% from the December 15th total of 58,700 shares. Based on an average daily volume of 112,000 shares, the short-interest ratio is presently 0.4 days. Currently, 0.3% of the shares of the company are sold short.

Institutional Investors Weigh In On LAVA Therapeutics

Large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in LAVA Therapeutics during the third quarter valued at about $32,000. XTX Topco Ltd purchased a new stake in LAVA Therapeutics during the second quarter valued at about $55,000. Finally, Pathway Financial Advisors LLC raised its position in LAVA Therapeutics by 70.8% during the third quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock valued at $170,000 after purchasing an additional 42,500 shares in the last quarter.

LAVA Therapeutics Price Performance

NASDAQ:LVTX traded up $0.00 during trading hours on Friday, hitting $0.94. 14,757 shares of the company’s stock traded hands, compared to its average volume of 123,351. LAVA Therapeutics has a 52 week low of $0.88 and a 52 week high of $6.47. The business’s fifty day simple moving average is $1.31 and its two-hundred day simple moving average is $1.64.

Wall Street Analyst Weigh In

Several brokerages have weighed in on LVTX. JMP Securities reissued a “market perform” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a report on Wednesday, December 11th. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. Citizens Jmp lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Leerink Partnrs lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, HC Wainwright cut their price target on LAVA Therapeutics from $6.00 to $2.00 and set a “buy” rating for the company in a report on Friday, December 20th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $3.33.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.